{
  "DOI": "10.1038/ejhg.2015.196",
  "ISSN": [
    "1018-4813",
    "1476-5438"
  ],
  "URL": "http://dx.doi.org/10.1038/ejhg.2015.196",
  "alternative-id": [
    "BFejhg2015196"
  ],
  "assertion": [
    {
      "group": {
        "label": "Article History",
        "name": "ArticleHistory"
      },
      "label": "Received",
      "name": "received",
      "order": 1,
      "value": "2 April 2015"
    },
    {
      "group": {
        "label": "Article History",
        "name": "ArticleHistory"
      },
      "label": "Revised",
      "name": "revised",
      "order": 2,
      "value": "7 July 2015"
    },
    {
      "group": {
        "label": "Article History",
        "name": "ArticleHistory"
      },
      "label": "Accepted",
      "name": "accepted",
      "order": 3,
      "value": "4 August 2015"
    },
    {
      "group": {
        "label": "Article History",
        "name": "ArticleHistory"
      },
      "label": "First Online",
      "name": "first_online",
      "order": 4,
      "value": "9 September 2015"
    },
    {
      "group": {
        "label": "Competing interests",
        "name": "EthicsHeading"
      },
      "name": "Ethics",
      "order": 1,
      "value": "N Hoogerbrugge is scientific consultant to AstraZeneca since June 2014. HP Eikesdal has received PARP inhibitors free of charge from AbbVie and AstraZeneca for use in clinical trials in patients with breast cancer. The other authors declare no conflict of interest."
    }
  ],
  "author": [
    {
      "affiliation": [],
      "family": "Høberg-Vetti",
      "given": "Hildegunn",
      "sequence": "first"
    },
    {
      "affiliation": [],
      "family": "Bjorvatn",
      "given": "Cathrine",
      "sequence": "additional"
    },
    {
      "affiliation": [],
      "family": "Fiane",
      "given": "Bent E",
      "sequence": "additional"
    },
    {
      "affiliation": [],
      "family": "Aas",
      "given": "Turid",
      "sequence": "additional"
    },
    {
      "affiliation": [],
      "family": "Woie",
      "given": "Kathrine",
      "sequence": "additional"
    },
    {
      "affiliation": [],
      "family": "Espelid",
      "given": "Helge",
      "sequence": "additional"
    },
    {
      "affiliation": [],
      "family": "Rusken",
      "given": "Tone",
      "sequence": "additional"
    },
    {
      "affiliation": [],
      "family": "Eikesdal",
      "given": "Hans Petter",
      "sequence": "additional"
    },
    {
      "affiliation": [],
      "family": "Listøl",
      "given": "Wenche",
      "sequence": "additional"
    },
    {
      "affiliation": [],
      "family": "Haavind",
      "given": "Marianne T",
      "sequence": "additional"
    },
    {
      "affiliation": [],
      "family": "Knappskog",
      "given": "Per M",
      "sequence": "additional"
    },
    {
      "affiliation": [],
      "family": "Haukanes",
      "given": "Bjørn Ivar",
      "sequence": "additional"
    },
    {
      "affiliation": [],
      "family": "Steen",
      "given": "Vidar M",
      "sequence": "additional"
    },
    {
      "affiliation": [],
      "family": "Hoogerbrugge",
      "given": "Nicoline",
      "sequence": "additional"
    }
  ],
  "container-title": [
    "European Journal of Human Genetics"
  ],
  "content-domain": {
    "crossmark-restriction": false,
    "domain": [
      "link.springer.com"
    ]
  },
  "created": {
    "date-parts": [
      [
        2015,
        9,
        9
      ]
    ],
    "date-time": "2015-09-09T10:26:39Z",
    "timestamp": 1441794399000
  },
  "deposited": {
    "date-parts": [
      [
        2022,
        1,
        5
      ]
    ],
    "date-time": "2022-01-05T09:12:05Z",
    "timestamp": 1641373925000
  },
  "indexed": {
    "date-parts": [
      [
        2024,
        3,
        28
      ]
    ],
    "date-time": "2024-03-28T18:03:35Z",
    "timestamp": 1711649015690
  },
  "is-referenced-by-count": 50,
  "issn-type": [
    {
      "type": "print",
      "value": "1018-4813"
    },
    {
      "type": "electronic",
      "value": "1476-5438"
    }
  ],
  "issue": "6",
  "issued": {
    "date-parts": [
      [
        2015,
        9,
        9
      ]
    ]
  },
  "journal-issue": {
    "issue": "6",
    "published-print": {
      "date-parts": [
        [
          2016,
          6
        ]
      ]
    }
  },
  "language": "en",
  "license": [
    {
      "URL": "https://creativecommons.org/licenses/by-nc-nd/4.0",
      "content-version": "tdm",
      "delay-in-days": 0,
      "start": {
        "date-parts": [
          [
            2015,
            9,
            9
          ]
        ],
        "date-time": "2015-09-09T00:00:00Z",
        "timestamp": 1441756800000
      }
    },
    {
      "URL": "https://creativecommons.org/licenses/by-nc-nd/4.0",
      "content-version": "vor",
      "delay-in-days": 0,
      "start": {
        "date-parts": [
          [
            2015,
            9,
            9
          ]
        ],
        "date-time": "2015-09-09T00:00:00Z",
        "timestamp": 1441756800000
      }
    }
  ],
  "link": [
    {
      "URL": "https://www.nature.com/articles/ejhg2015196.pdf",
      "content-type": "application/pdf",
      "content-version": "vor",
      "intended-application": "text-mining"
    },
    {
      "URL": "https://www.nature.com/articles/ejhg2015196",
      "content-type": "text/html",
      "content-version": "vor",
      "intended-application": "text-mining"
    },
    {
      "URL": "https://www.nature.com/articles/ejhg2015196.pdf",
      "content-type": "application/pdf",
      "content-version": "vor",
      "intended-application": "similarity-checking"
    }
  ],
  "member": "297",
  "page": "881-888",
  "prefix": "10.1038",
  "published": {
    "date-parts": [
      [
        2015,
        9,
        9
      ]
    ]
  },
  "published-online": {
    "date-parts": [
      [
        2015,
        9,
        9
      ]
    ]
  },
  "published-print": {
    "date-parts": [
      [
        2016,
        6
      ]
    ]
  },
  "publisher": "Springer Science and Business Media LLC",
  "reference": [
    {
      "key": "BFejhg2015196_CR1",
      "unstructured": "Ferlay J, Soerjomataram I, Ervik M et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer; 2013. Available from http://globocan.iarc.fr (accessed on 07 July 2015)."
    },
    {
      "DOI": "10.1097/GCO.0b013e328332dca3",
      "author": "AW Kurian",
      "doi-asserted-by": "publisher",
      "first-page": "72",
      "journal-title": "Curr Opin Obstet Gynecol",
      "key": "BFejhg2015196_CR2",
      "unstructured": "Kurian AW : BRCA1 and BRCA2 mutations across race and ethnicity: distribution and clinical implications. Curr Opin Obstet Gynecol 2010; 22: 72–78.",
      "volume": "22",
      "year": "2010"
    },
    {
      "DOI": "10.1016/j.ygyno.2011.01.020",
      "author": "S Zhang",
      "doi-asserted-by": "publisher",
      "first-page": "353",
      "journal-title": "Gynecol Oncol",
      "key": "BFejhg2015196_CR3",
      "unstructured": "Zhang S, Royer R, Li S et al: Frequencies of BRCA1 and BRCA2 mutations among 1,342 unselected patients with invasive ovarian cancer. Gynecol Oncol 2011; 121: 353–357.",
      "volume": "121",
      "year": "2011"
    },
    {
      "DOI": "10.1200/JCO.2011.39.8545",
      "author": "K Alsop",
      "doi-asserted-by": "publisher",
      "first-page": "2654",
      "journal-title": "J Clin Oncol",
      "key": "BFejhg2015196_CR4",
      "unstructured": "Alsop K, Fereday S, Meldrum C et al: BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group. J Clin Oncol 2012; 30: 2654–2663.",
      "volume": "30",
      "year": "2012"
    },
    {
      "DOI": "10.1093/hmg/ddu172",
      "author": "H Song",
      "doi-asserted-by": "publisher",
      "first-page": "4703",
      "journal-title": "Hum Mol Genet",
      "key": "BFejhg2015196_CR5",
      "unstructured": "Song H, Cicek MS, Dicks E et al: The contribution of deleterious germline mutations in BRCA1, BRCA2 and the mismatch repair genes to ovarian cancer in the population. Hum Mol Genet 2014; 23: 4703–4709.",
      "volume": "23",
      "year": "2014"
    },
    {
      "DOI": "10.1016/j.ejca.2007.04.023",
      "author": "P Moller",
      "doi-asserted-by": "publisher",
      "first-page": "1713",
      "journal-title": "Eur J Cancer",
      "key": "BFejhg2015196_CR6",
      "unstructured": "Moller P, Hagen AI, Apold J et al: Genetic epidemiology of BRCA mutations—family history detects less than 50% of the mutation carriers. Eur J Cancer 2007; 43: 1713–1717.",
      "volume": "43",
      "year": "2007"
    },
    {
      "DOI": "10.1007/s10689-012-9560-4",
      "author": "P Gaj",
      "doi-asserted-by": "publisher",
      "first-page": "623",
      "journal-title": "Fam Cancer",
      "key": "BFejhg2015196_CR7",
      "unstructured": "Gaj P, Kluska A, Nowakowska D et al: High frequency of BRCA1 founder mutations in Polish women with nonfamilial breast cancer. Fam Cancer 2012; 11: 623–628.",
      "volume": "11",
      "year": "2012"
    },
    {
      "DOI": "10.1200/JCO.2014.57.1414",
      "author": "FJ Couch",
      "doi-asserted-by": "publisher",
      "first-page": "304",
      "journal-title": "J Clin Oncol",
      "key": "BFejhg2015196_CR8",
      "unstructured": "Couch FJ, Hart SN, Sharma P et al: Inherited mutations in 17 breast cancer susceptibility genes among a large triple-negative breast cancer cohort unselected for family history of breast cancer. J Clin Oncol 2015; 33: 304–311.",
      "volume": "33",
      "year": "2015"
    },
    {
      "DOI": "10.1200/JCO.2004.04.086",
      "author": "MD Schwartz",
      "doi-asserted-by": "publisher",
      "first-page": "1823",
      "journal-title": "J Clin Oncol",
      "key": "BFejhg2015196_CR9",
      "unstructured": "Schwartz MD, Lerman C, Brogan B et al: Impact of BRCA1/BRCA2 counselling and testing on newly diagnosed breast cancer patients. J Clin Oncol 2004; 22: 1823–1829.",
      "volume": "22",
      "year": "2004"
    },
    {
      "DOI": "10.1093/jnci/djn442",
      "author": "TR Rebbeck",
      "doi-asserted-by": "publisher",
      "first-page": "80",
      "journal-title": "J Natl Cancer Inst",
      "key": "BFejhg2015196_CR10",
      "unstructured": "Rebbeck TR, Kauff ND, Domchek SM : Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers. J Natl Cancer Inst 2009; 101: 80–87.",
      "volume": "101",
      "year": "2009"
    },
    {
      "DOI": "10.1093/jnci/djt095",
      "author": "N Mavaddat",
      "doi-asserted-by": "publisher",
      "first-page": "812",
      "journal-title": "J Natl Cancer Inst",
      "key": "BFejhg2015196_CR11",
      "unstructured": "Mavaddat N, Peock S, Frost D et al: Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE. J Natl Cancer Inst 2013; 105: 812–822.",
      "volume": "105",
      "year": "2013"
    },
    {
      "DOI": "10.1136/jmedgenet-2013-101974",
      "author": "RM Brohet",
      "doi-asserted-by": "publisher",
      "first-page": "98",
      "journal-title": "J Med Genet",
      "key": "BFejhg2015196_CR12",
      "unstructured": "Brohet RM, Velthuizen ME, Hogervorst FB et al: Breast and ovarian cancer risks in a large series of clinically ascertained families with a high proportion of BRCA1 and BRCA2 Dutch founder mutations. J Med Genet 2014; 51: 98–107.",
      "volume": "51",
      "year": "2014"
    },
    {
      "DOI": "10.1158/1055-9965.EPI-11-1196",
      "author": "EA Heijnsdijk",
      "doi-asserted-by": "publisher",
      "first-page": "1458",
      "journal-title": "Cancer Epidemiol Biomarkers Prev",
      "key": "BFejhg2015196_CR13",
      "unstructured": "Heijnsdijk EA, Warner E, Gilbert FJ et al: Differences in natural history between breast cancers in BRCA1 and BRCA2 mutation carriers and effects of MRI screening-MRISC, MARIBS, and Canadian studies combined. Cancer Epidemiol Biomarkers Prev 2012; 21: 1458–1468.",
      "volume": "21",
      "year": "2012"
    },
    {
      "DOI": "10.1007/s10549-014-2931-9",
      "author": "DG Evans",
      "doi-asserted-by": "publisher",
      "first-page": "663",
      "journal-title": "Breast Cancer Res Treat",
      "key": "BFejhg2015196_CR14",
      "unstructured": "Evans DG, Nisha K, Yit L et al: MRI breast screening in high-risk women: cancer detection and survival analysis. Breast Cancer Res Treat 2014; 145: 663–672.",
      "volume": "145",
      "year": "2014"
    },
    {
      "DOI": "10.1200/JCO.2004.04.188",
      "author": "TR Rebbeck",
      "doi-asserted-by": "publisher",
      "first-page": "1055",
      "journal-title": "J Clin Oncol",
      "key": "BFejhg2015196_CR15",
      "unstructured": "Rebbeck TR, Friebel T, Lynch HT et al: Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol 2004; 22: 1055–1062.",
      "volume": "22",
      "year": "2004"
    },
    {
      "DOI": "10.1007/s10549-013-2765-x",
      "author": "SL Ingham",
      "doi-asserted-by": "publisher",
      "first-page": "611",
      "journal-title": "Breast Cancer Res Treat",
      "key": "BFejhg2015196_CR16",
      "unstructured": "Ingham SL, Sperrin M, Baildam A et al: Risk-reducing surgery increases survival in BRCA1/2 mutation carriers unaffected at time of family referral. Breast Cancer Res Treat 2013; 142: 611–618.",
      "volume": "142",
      "year": "2013"
    },
    {
      "DOI": "10.1186/1897-4287-2-1-19",
      "author": "I van Oostrom",
      "doi-asserted-by": "publisher",
      "first-page": "19",
      "journal-title": "Hered Cancer Clin Pract",
      "key": "BFejhg2015196_CR17",
      "unstructured": "van Oostrom I, Tibben A : A counselling model for BRCA1/2 genetic susceptibility testing. Hered Cancer Clin Pract 2004; 2: 19–23.",
      "volume": "2",
      "year": "2004"
    },
    {
      "DOI": "10.1007/s12687-011-0042-4",
      "author": "D Gadzicki",
      "doi-asserted-by": "publisher",
      "first-page": "53",
      "journal-title": "J Community Genet",
      "key": "BFejhg2015196_CR18",
      "unstructured": "Gadzicki D, Evans DG, Harris H et al: Genetic testing for familial/hereditary breast cancer-comparison of guidelines and recommendations from the UK, France, the Netherlands and Germany. J Community Genet 2011; 2: 53–69.",
      "volume": "2",
      "year": "2011"
    },
    {
      "DOI": "10.1007/s10549-013-2669-9",
      "author": "P Pujol",
      "doi-asserted-by": "publisher",
      "first-page": "135",
      "journal-title": "Breast Cancer Res Treat",
      "key": "BFejhg2015196_CR19",
      "unstructured": "Pujol P, Lyonnet DS, Frebourg T et al: Lack of referral for genetic counselling and testing in BRCA1/2 and Lynch syndromes: a nationwide study based on 240,134 consul'ta'tions and 134,652 genetic tests. Breast Cancer Res Treat 2013; 141: 135–144.",
      "volume": "141",
      "year": "2013"
    },
    {
      "DOI": "10.1038/sj.bjc.6604830",
      "author": "KA Metcalfe",
      "doi-asserted-by": "publisher",
      "first-page": "421",
      "journal-title": "Br J Cancer",
      "key": "BFejhg2015196_CR20",
      "unstructured": "Metcalfe KA, Finch A, Poll A et al: Breast cancer risks in women with a family history of breast or ovarian cancer who have tested negative for a BRCA1 or BRCA2 mutation. Br J Cancer 2009; 100: 421–425.",
      "volume": "100",
      "year": "2009"
    },
    {
      "DOI": "10.1093/annonc/mdt384",
      "author": "JM Lee",
      "doi-asserted-by": "publisher",
      "first-page": "32",
      "journal-title": "Ann Oncol",
      "key": "BFejhg2015196_CR21",
      "unstructured": "Lee JM, Ledermann JA, Kohn EC : PARP inhibitors for BRCA1/2 mutation-associated and BRCA-like malignancies. Ann Oncol 2014; 25: 32–40.",
      "volume": "25",
      "year": "2014"
    },
    {
      "author": "AS Sie",
      "first-page": "143",
      "journal-title": "Fam Cancer",
      "key": "BFejhg2015196_CR22",
      "unstructured": "Sie AS, van Zelst-Stams WA, Spruijt L et al: More breast cancer patients prefer BRCA-mutation testing without prior face-to-face genetic counselling. Fam Cancer 2014; 13: 143–151.",
      "volume": "13",
      "year": "2014"
    },
    {
      "DOI": "10.1002/humu.20880",
      "author": "SE Plon",
      "doi-asserted-by": "publisher",
      "first-page": "1282",
      "journal-title": "Hum Mutat",
      "key": "BFejhg2015196_CR23",
      "unstructured": "Plon SE, Eccles DM, Easton D et al: Sequence variant classification and reporting: recommendations for improving the interpretation of cancer susceptibility genetic test results. Hum Mutat 2008; 29: 1282–1291.",
      "volume": "29",
      "year": "2008"
    },
    {
      "DOI": "10.1136/jmg.2003.017996",
      "author": "DG Evans",
      "doi-asserted-by": "publisher",
      "first-page": "474",
      "journal-title": "J Med Genet",
      "key": "BFejhg2015196_CR24",
      "unstructured": "Evans DG, Eccles DM, Rahman N et al: A new scoring system for the chances of identifying a BRCA1/2 mutation outperforms existing models including BRCAPRO. J Med Genet 2004; 41: 474–480.",
      "volume": "41",
      "year": "2004"
    },
    {
      "DOI": "10.1136/jmg.2009.067850",
      "author": "DG Evans",
      "doi-asserted-by": "publisher",
      "first-page": "811",
      "journal-title": "J Med Genet",
      "key": "BFejhg2015196_CR25",
      "unstructured": "Evans DG, Lalloo F, Cramer A et al: Addition of pathology and biomarker information significantly improves the performance of the Manchester scoring system for BRCA1 and BRCA2 testing. J Med Genet 2009; 46: 811–817.",
      "volume": "46",
      "year": "2009"
    },
    {
      "DOI": "10.1111/j.1600-0447.1983.tb09716.x",
      "author": "AS Zigmond",
      "doi-asserted-by": "publisher",
      "first-page": "361",
      "journal-title": "Acta Psychiatr Scand",
      "key": "BFejhg2015196_CR26",
      "unstructured": "Zigmond AS, Snaith RP : The hospital anxiety and depression scale. Acta Psychiatr Scand 1983; 67: 361–370.",
      "volume": "67",
      "year": "1983"
    },
    {
      "DOI": "10.1016/S0022-3999(01)00296-3",
      "author": "I Bjelland",
      "doi-asserted-by": "publisher",
      "first-page": "69",
      "journal-title": "J Psychosom Res",
      "key": "BFejhg2015196_CR27",
      "unstructured": "Bjelland I, Dahl AA., Haug TT, Neckelmann D : The validity of the Hospital Anxiety and Depression Scale. An updated literature review. J Psychosom Res 2002; 52: 69–77.",
      "volume": "52",
      "year": "2002"
    },
    {
      "DOI": "10.3109/0284186X.2011.577446",
      "author": "M Hoyer",
      "doi-asserted-by": "publisher",
      "first-page": "1015",
      "journal-title": "Acta Oncol",
      "key": "BFejhg2015196_CR28",
      "unstructured": "Hoyer M, Johansson B, Nordin K et al: Health-related quality of life among women with breast cancer - a population-based study. Acta Oncol 2011; 50: 1015–1026.",
      "volume": "50",
      "year": "2011"
    },
    {
      "DOI": "10.1002/pon.3253",
      "author": "L Stafford",
      "doi-asserted-by": "publisher",
      "first-page": "2071",
      "journal-title": "Psychooncology",
      "key": "BFejhg2015196_CR29",
      "unstructured": "Stafford L, Judd F, Gibson P, Komiti A, Mann GB, Quinn M : Screening for depression and anxiety in women with breast and gynaecologic cancer: course and prevalence of morbidity over 12 months. Psychooncology 2013; 22: 2071–2078.",
      "volume": "22",
      "year": "2013"
    },
    {
      "author": "IK Larsen",
      "key": "BFejhg2015196_CR30",
      "unstructured": "Larsen IK, Larønningen S, Johannesen TB et al. (eds): Cancer in Norway 2012—Cancer Incidence, Mortality, Survival and Prevalence in Norway. Oslo, Norway: Cancer Registry of Norway, 2014.",
      "volume-title": "Cancer in Norway 2012—Cancer Incidence, Mortality, Survival and Prevalence in Norway",
      "year": "2014"
    },
    {
      "DOI": "10.1200/JCO.2013.51.4661",
      "author": "ME Wood",
      "doi-asserted-by": "publisher",
      "first-page": "824",
      "journal-title": "J Clin Oncol",
      "key": "BFejhg2015196_CR31",
      "unstructured": "Wood ME, Kadlubek P, Pham TH et al: Quality of cancer family history and referral for genetic counselling and testing among oncology practices: a pilot test of quality measures as part of the American Society of Clinical Oncology Quality Oncology Practice Initiative. J Clin Oncol 2014; 32: 824–829.",
      "volume": "32",
      "year": "2014"
    },
    {
      "DOI": "10.1200/JCO.2014.56.2942",
      "author": "AS Sie",
      "doi-asserted-by": "publisher",
      "first-page": "3343",
      "journal-title": "J Clin Oncol",
      "key": "BFejhg2015196_CR32",
      "unstructured": "Sie AS, Brunner HG, Hoogerbrugge N : Easy-to-use decision aids for improved cancer family history collection and use among oncology practices. J Clin Oncol 2014; 32: 3343.",
      "volume": "32",
      "year": "2014"
    },
    {
      "DOI": "10.1245/s10434-012-2460-x",
      "author": "J Christie",
      "doi-asserted-by": "publisher",
      "first-page": "4003",
      "journal-title": "Ann Surg Oncol",
      "key": "BFejhg2015196_CR33",
      "unstructured": "Christie J, Quinn GP, Malo TM et al: Cognitive and psychological impact of BRCA genetic counselling in before and after definitive surgery breast cancer patients. Ann Surg Oncol 2012; 19: 4003–4011.",
      "volume": "19",
      "year": "2012"
    },
    {
      "DOI": "10.1007/s00127-012-0594-6",
      "author": "A Brunes",
      "doi-asserted-by": "publisher",
      "first-page": "745",
      "journal-title": "Soc Psychiatry Psychiatr Epidemiol",
      "key": "BFejhg2015196_CR34",
      "unstructured": "Brunes A, Augestad LB, Gudmundsdottir SL : Personality, physical activity, and symptoms of anxiety and depression: the HUNT study. Soc Psychiatry Psychiatr Epidemiol 2013; 48: 745–756.",
      "volume": "48",
      "year": "2013"
    },
    {
      "DOI": "10.1136/jmedgenet-2012-101037",
      "author": "AB Spurdle",
      "doi-asserted-by": "publisher",
      "first-page": "525",
      "journal-title": "J Med Genet",
      "key": "BFejhg2015196_CR35",
      "unstructured": "Spurdle AB, Whiley PJ, Thompson B et al: BRCA1 R1699Q variant displaying ambiguous functional abrogation confers intermediate breast and ovarian cancer risk. J Med Genet 2012; 49: 525–532.",
      "volume": "49",
      "year": "2012"
    }
  ],
  "reference-count": 35,
  "references-count": 35,
  "resource": {
    "primary": {
      "URL": "https://www.nature.com/articles/ejhg2015196"
    }
  },
  "score": 0,
  "short-container-title": [
    "Eur J Hum Genet"
  ],
  "source": "Crossref",
  "title": [
    "BRCA1/2 testing in newly diagnosed breast and ovarian cancer patients without prior genetic counselling: the DNA-BONus study"
  ],
  "type": "journal-article",
  "update-policy": "http://dx.doi.org/10.1007/springer_crossmark_policy",
  "volume": "24"
}